Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Current insight into the regulation of PD-L1 in cancer
Zhuandi Liu, Xibao Yu, Ling Xu, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

Recent advances in targeted strategies for triple-negative breast cancer
Shuangli Zhu, Yuze Wu, Bin Song, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 112
Exploiting innate immunity for cancer immunotherapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 78
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
Mengke Niu, Ming Yi, Yuze Wu, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 46
Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion
Junli Lu, Yiming Luo, Dean Rao, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 37
Targeting TIGIT for cancer immunotherapy: recent advances and future directions
Peng Zhang, Xinyuan Liu, Zhuoyu Gu, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 28
The role of the immunosuppressive PD-1/PD-L1 checkpoint pathway in the aging process and age-related diseases
Antero Salminen
Journal of Molecular Medicine (2024) Vol. 102, Iss. 6, pp. 733-750
Open Access | Times Cited: 21
Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside
Yue Yin, Weibo Feng, Jie Chen, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 19
Mitochondria Energy Metabolism Depression as Novel Adjuvant to Sensitize Radiotherapy and Inhibit Radiation Induced‐Pulmonary Fibrosis
Zaigang Zhou, Xin Jiang, Yi Lei, et al.
Advanced Science (2024) Vol. 11, Iss. 26
Open Access | Times Cited: 17
Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the “all-around warrior” in immunotherapy
Qiang Liu, Yujing Guan, Shenglong Li
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 15
Recent progress, perspectives, and issues of engineered PD-L1 regulation nano-system to better cure tumor: A review
Zaigang Zhou, Haoxiang Wang, Jie Li, et al.
International Journal of Biological Macromolecules (2023) Vol. 254, pp. 127911-127911
Closed Access | Times Cited: 22
Crosstalk between colorectal CSCs and immune cells in tumorigenesis, and strategies for targeting colorectal CSCs
Qi Zhao, Hong Zong, Pingping Zhu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies
Juanjuan Shang, Shunfeng Hu, Xin Wang
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 8
A new era in cancer treatment: harnessing ZIF-8 nanoparticles for PD-1 inhibitor delivery
Farangis Rastin, Mahsa Akbari Oryani, Sonia Iranpour, et al.
Journal of Materials Chemistry B (2023) Vol. 12, Iss. 4, pp. 872-894
Closed Access | Times Cited: 18
Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway
Zhijie Wang, L. Yuan, Xiaotong Liao, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6027-6043
Closed Access | Times Cited: 7
Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors
Yuze Wu, Ming Yi, Mengke Niu, et al.
Cancer Communications (2024) Vol. 44, Iss. 7, pp. 739-760
Open Access | Times Cited: 7
Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1
Ana Dillen, Indy Bui, Megan Jung, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1237-1237
Open Access | Times Cited: 6
Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
Kostas A. Papavassiliou, Γεώργιος Μαρίνος, Athanasios G. Papavassiliou
Cancers (2023) Vol. 15, Iss. 2, pp. 386-386
Open Access | Times Cited: 14
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) as an undetermined tool in tumor cells
Parviz Azimnasab-sorkhabi, Maryam Soltani-asl, José Roberto Kfoury
Human Cell (2023) Vol. 36, Iss. 4, pp. 1225-1232
Closed Access | Times Cited: 14
A novel PD-1/PD-L1 pathway-related seven-gene signature for the development and validation of the prognosis prediction model for breast cancer
Peng Zhang, Jingjing Yang, Xiaolong Zhong, et al.
Translational Cancer Research (2024) Vol. 13, Iss. 3, pp. 1554-1566
Open Access | Times Cited: 5
The predictive role of PD-L1 in head and neck cancer: A systematic review and meta-analysis
Alberto Paderno, Fausto Petrelli, Luigi Lorini, et al.
Oral Oncology (2024) Vol. 153, pp. 106799-106799
Closed Access | Times Cited: 5
Semaphorin7A and PD-L1 cooperatively drive immunosuppression during mammary involution and breast cancer
Alan M. Elder, H. L. Fairchild, Kelsey Kines, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Combined PARP14 inhibition and PD-1 blockade promotes cytotoxic T cell quiescence and modulates macrophage polarization in relapsed melanoma
Rotem Leshem, Kieran N. Sefton, Chun Wai Wong, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e010683-e010683
Open Access
Exploring Immune Checkpoint Inhibitors: Focus on PD-1/PD-L1 Axis and Beyond
Durre Aden, Samreen Zaheer, Niti Sureka, et al.
Pathology - Research and Practice (2025) Vol. 269, pp. 155864-155864
Closed Access
Capsanthin inhibits migration and reduces N-linked glycosylation of PD-L1 via the EZH2-PD-L1 axis in triple-negative breast cancer brain metastasis
Yi‐Chung Chien, Jiayan Wu, Liang‐Chih Liu, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Programmed Cell Death Ligand as a Biomarker for Response to Immunotherapy: Contribution of Mass Spectrometry-Based Analysis
Marco Agostini, Pietro Traldi, Mahmoud Hamdan
Cancers (2025) Vol. 17, Iss. 6, pp. 1001-1001
Open Access
Page 1 - Next Page

Scroll to top